Effect of NSAIDs on the recurrence of nonmelanoma skin cancer

International Journal of Cancer

Volumn 119, Issue 3, 2006, Pages 682-686

  Grau, Maria V ^a,e   Baron, John A ^a   Langholz, Bryan ^b   Karagas, Margaret ^a   Greenberg, E Robert ^a   Stukel, Therese A ^c   Mandel, Jack S ^d  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d EMORY UNIVERSITY   (United States)

^e Evergreen Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA CAROTENE; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ADULT; ARTICLE; BASAL CELL CARCINOMA; CANCER RECURRENCE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EXPOSURE; FEMALE; FOLLOW UP; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; NONMELANOMA SKIN CANCER; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SKIN CANCER; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; BETA CAROTENE; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ODDS RATIO; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS; REGRESSION ANALYSIS; RISK FACTORS; SKIN NEOPLASMS;

EID: 33745434389     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21878     Document Type: Article

References (55)

1. Huang C, Ma WY, Hanenberger D, Cleary MP, Bowden GT, Dong Z. Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice. J Biol Chem 1997;272:26325-31.
2. Bair WB, III, Hart N, Einspahr J, Liu G, Dong Z, Alberts D, Bowden GT. Inhibitory effects of sodium salicylate and acetylsalicylic acid on UVB-induced mouse skin carcinogenesis. Cancer Epidemiol Biomarkers Prev 2002;11:1645-52.
3. Marks F, Furstenberger G, Neufang G, Muller-Decker K. Mouse skin as a model for cancer chemoprevention by nonsteroidal anti-inflammatory drugs. Recent Results Cancer Res 2003;163:46-57.
4. Reeve VE, Matheson MJ, Bosnic M, Boehm-Wilcox C. The protective effect of indomethacin on photocarcinogenesis in hairless mice. Cancer Lett 1995;95:213-19.
5. Fischer SM, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubet RA, Conti CJ. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 1999;25:231-40.
6. Bode AM, Dong Z. Signal transduction pathways: targets for chemoprevention of skin cancer. Lancet Oncol 2000;1:181-8.
7. Ma WY, Huang C, Dong Z. Inhibition of ultraviolet C irradiation-induced AP-1 activity by aspirin is through inhibition of JNKs but not erks or P38 MAP kinase. Im J Oncol 1998;12:565-8.
8. al-Waili NS. Indomethacin in basal cell carcinoma. J Pak Med Assoc 1989;39:134-6.
9. Smith KJ, Germain M, Skelton H. Bowen's disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a cox inhibitor, sulindac: potential applications for this combination of immunotherapy. Dermatol Surg 2001;27:143-6.
10. al-Saleem T. Nonsteroidal anti-inflammatory drugs in skin cancer: revisited. J Natl Cancer Inst 1993;85:581-2.
11. Arber N. Do NSAIDs prevent colorectal cancer? Can J Gastroenterol 2000;14:299-307.
12. Asano TK, McLeod RS. Non steroidal anti-inflammatory drugs (NSAID) and aspirin for preventing colorectal adenomas and carcinomas. Cochrane Database of Syst Rev 2004;2:CD004079.
13. Asano TK, McLeod RS. Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: a systematic review. Dis Colon Rectum 2004;47:665-73.
14. Breuer-Katschinski B, Nemes K, Rump B, Leiendecker B, Marr A, Breuer N, Goebell H. Long-term use of nonsteroidal antiinflammatory drugs and the risk of colorectal adenomas. The Colorectal Adenoma Study Group. Digestion 2000;61:129-34.
15. Tangrea JA, Albert PS, Lanza E, Woodson K, Corle D, Hasson M, Burt R, Caan B, Paskett E, Iber F, Kikendall JW, Lance P, et al. Nonsteroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States). Cancer Causes Control 2003;14:403-11.
16. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121:241-6.
17. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-14.
18. Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, Couturier D, Coste T, Little J, Chaussade S. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003;125:328-36.
19. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-16.
20. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90.
21. (Erratum appears in N Engl J Med 2003 May 8;348:1939.)
22. Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, Ekbom A, Baron JA. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003;88:1687-92.
23. Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 2003;88:684-8.
24. Martinez JC, Otley CC. The management of melanoma and nonmelanoma skin cancer: a review for the primary care physician. Mayo Clin Proc 2001;76:1253-65.
25. MacKie RM. Awareness, knowledge and attitudes to basal cell carcinoma and actinic keratoses among the general public within Europe. J Eur Acad Dermatol Venereol 2004;18:552-5.
26. Wolf JE, Jr, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001;40:709-13.
27. Nelson C, Rigel D, Smith S, Swanson N, Wolf J, Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol 2004;3:401-7.
28. Greenberg ER, Baron JA, Stukel TA, Stevens MM, Mandel JS, Spencer SK, Elias PM, Lowe N, Nierenberg DW, Bayrd G, et al. A clinical trial of β-carotene to prevent basal-cell and squamous-cell cancers of the skin. The Skin Cancer Prevention Study Group. N Engl J Med 1990;323:789-95.
29. Erratum appears in N Engl J Med 1991 Oct 31;325:1324.
30. Greenberg ER, Baron JA, Stevens MM, Stukel TA, Mandel JS, Spencer SK, Elias PM, Lowe N, Nierenberg DN, Bayrd G, et al. The Skin Cancer Prevention Study: design of a clinical trial of β-carotene among persons at high risk for nonmelanoma skin cancer. Control Clin Trials 1989;10:153-66.
31. Abbott RD. Logistic regression in survival analysis. Am J Epidemiol 1985;121:465-71.
32. IARC Working Group on the Evaluation of Cancer Preventive Agents. IARC handbooks for cancer prevention. Vol. 1: Non-steroidal anti-inflammatory drugs. International Agency for Research on Cancer, WHO: Lion, France, 1997.
33. Anderson WF, Umar A, Viner JL, Hawk ET. The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Des 2002;8:1035-62.
34. Anderson WF, Umar A, Hawk ET. Cyclooxygenase inhibition in cancer prevention and treatment. Expert Opin Pharmacother 2003;4:2193-204.
35. Friedman ES, LaNatra N, Stiller MJ. NSAIDs in dermatologic therapy: review and preview. J Cutan Med Surgery. 2002;6:449-59.
36. Pentland AP, Schoggins JW, Scott GA, Khan KN, Han R. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 1999;20:1939-44.
37. Orengo IF, Gerguis J, Phillips R, Guevara A, Lewis AT, Black HS. Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin cancer: a study in the hairless mouse model. Arch Dermatol 2002;138:751-5.
38. Akita Y, Kozaki K, Nakagawa A, Saito T, Ito S, Tamada Y, Fujiwara S, Nishikawa N, Uchida K, Yoshikawa K, Noguchi T, Miyaishi O, et al. Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity. Br J Dermatol 2004;151:472-80.
39. Rivers JK, McLean DI. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol 1997;133:1239-42.
40. Sniff SJ, Rigas B. The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J Exp Med 1999;190:445-50.
41. Fischer SM. Is cyclooxygenase-2 important in skin carcinogenesis? J Environ Pathol Toxicol Oncol 2002;21:183-91.
42. Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer J, Pentland AP. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998;19:723-9.
43. An KP, Athar M, Tang X, Katiyar SK, Russo J, Beech J, Aszterbaum M, Kopelovich L, Epstein EH, Jr, Mukhtar H, Bickers DR. Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochem Photobiol 2002;76:73-80.
44. Umar A, Viner JL, Anderson WF, Hawk ET. Development of COX inhibitors in cancer prevention and therapy. Am J Clin Oncol 2003;26:S48-S57.
45. Higashi Y, Kanekura T, Kanzaki T. Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression. Int J Cancer 2000;86:667-71.
46. Muller-Decker K, Reinerth G, Krieg P, Zimmermann R, Heise H, Bayerl C, Marks F, Furstenberger G. Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin. Int J Cancer 1999;82:648-56.
47. Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, Dunson DB, Rogan EG, Morham SG, Smart RC, Langenbach R. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 2002;62:3395-401.
48. de Gruijl FR, Photobiology of photocarcinogenesis. Photochem Photobiol 1996;63:372-5.
49. Rosso S, Zanetti R, Martinez C, Tormo MJ, Schraub S, Sancho-Garnier H, Franceschi S, Gafa L, Perea E, Navarro C, Laurent R, Schrameck C, et al. The multicentre south European study 'Helios'. II. Different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. Br J Cancer 1447;73:1447-54.
50. Tellechea O, Reis JP, Domingues JC, Baptista AP. Monoclonal antibody Ber EP4 distinguishes basal-cell carcinoma from squamous-cell carcinoma of the skin. Am J Dermatopathol 1993;15:452-5.
51. Ridky TW, Khavari PA. Pathways sufficient to induce epidermal carcinogenesis. Cell Cycle 2004;3:621-4.
52. al-Sader MH, Doyle E, Kay EW, Bennett M, Walsh CB, Curran B, Milbum C, Leader M. Proliferation indexes-a comparison between cutaneous basal and squamous cell carcinomas. J Clin Pathol 1996;49:549-51.
53. Morales-Ducret CR, van de Rijn M, LeBrun DP, Smoller BR. bcl-2 expression in primary malignancies of the skin. Arch Dermatol 1995;131:909-12.
54. O'Grady A, O'Kelly P, Murphy GM, Leader M, Kay E. COX-2 expression correlates with microvessel density in non-melanoma skin cancer from renal transplant recipients and immunocompetent individuals. Hum Pathol 1549;35:1549-55.
55. Bowden J, Brennan PA, Umar T, Cronin A. Expression of vascular endothelial growth factor in basal cell carcinoma and cutaneous squamous cell carcinoma of the head and neck. J Cutan Pathol 2002;29:585-9.